News > DCGI Approves Mylan’s Remdesivir at Rs 4,800 Per Vial in India
DCGI Approves Mylan’s Remdesivir at Rs 4,800 Per Vial in India
Chemin digest | 07/07/2020 09:52 PM | Click to read full article
Mylan NV on 06th July said it has received approval from Indian drugs regulator DCGI to manufacture and market its Remdesivir for restricted emergency use in the country for the treatment of COVID-19.
The drug will be priced at Rs 4,800 per 100 mg vial and would be available to the patients in this month, it added. The company joins domestic pharma firm Cipla and Hetero who have already received permissions.
